123 related articles for article (PubMed ID: 35536994)
1. Use of Cabozantinib to Treat MET -amplified Pediatric Colorectal Cancer.
Fukui S; Umeda K; Kubota H; Iwai A; Akazawa R; Isobe K; Tanaka K; Kouzuki K; Kawabata N; Saida S; Kato I; Hiramatsu H; Itatani Y; Funakoshi T; Adachi S; Takita J
J Pediatr Hematol Oncol; 2023 Apr; 45(3):e423-e426. PubMed ID: 35536994
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
Jia J; Howard L; Liu Y; Starr MD; Brady JC; Niedzwiecki D; Strickler JH; Nixon AB
Cancer Chemother Pharmacol; 2022 Mar; 89(3):413-422. PubMed ID: 35171350
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model.
Sun Y; Sun L; An Y; Shen X
Med Sci Monit; 2015 Aug; 21():2316-21. PubMed ID: 26255947
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.
Wedekind MF; Ranalli M; Shah N
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28417541
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
[TBL] [Abstract][Full Text] [Related]
8. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Drilon A; Rekhtman N; Arcila M; Wang L; Ni A; Albano M; Van Voorthuysen M; Somwar R; Smith RS; Montecalvo J; Plodkowski A; Ginsberg MS; Riely GJ; Rudin CM; Ladanyi M; Kris MG
Lancet Oncol; 2016 Dec; 17(12):1653-1660. PubMed ID: 27825636
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
Shang R; Song X; Wang P; Zhou Y; Lu X; Wang J; Xu M; Chen X; Utpatel K; Che L; Liang B; Cigliano A; Evert M; Calvisi DF; Chen X
Gut; 2021 Sep; 70(9):1746-1757. PubMed ID: 33144318
[TBL] [Abstract][Full Text] [Related]
12. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
13. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Neal JW; Dahlberg SE; Wakelee HA; Aisner SC; Bowden M; Huang Y; Carbone DP; Gerstner GJ; Lerner RE; Rubin JL; Owonikoko TK; Stella PJ; Steen PD; Khalid AA; Ramalingam SS;
Lancet Oncol; 2016 Dec; 17(12):1661-1671. PubMed ID: 27825638
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract][Full Text] [Related]
16. Response to cabozantinib in renal cell carcinoma with cardiac metastases.
Stellato M; Cursano MC; Citarella F; Pantano F; Russano M; Dell' Aquila E; Vincenzi B; Tonini G; Santini D
Anticancer Drugs; 2020 Mar; 31(3):314-318. PubMed ID: 31929349
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
Strickler JH; Rushing CN; Uronis HE; Morse MA; Niedzwiecki D; Blobe GC; Moyer AN; Bolch E; Webb R; Haley S; Hatch AJ; Altomare IP; Sherrill GB; Chang DZ; Wells JL; Hsu SD; Jia J; Zafar SY; Nixon AB; Hurwitz HI
Oncologist; 2021 Jun; 26(6):465-e917. PubMed ID: 33469991
[TBL] [Abstract][Full Text] [Related]
18. RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.
Wang Y; Xu Y; Wang X; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
Medicine (Baltimore); 2019 Jan; 98(3):e14120. PubMed ID: 30653139
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Yang S; Zhang X; Qu H; Qu B; Yin X; Zhao H
Cancer Gene Ther; 2020 May; 27(5):368-377. PubMed ID: 31182761
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
